Member Info for Brand

Thank you to those that shared their knowledge on this one. Much appreciated.

Wait, Sotrovimab?

'Two of the monoclonal antibody therapies that have helped keep people with COVID-19 from needing to be hospitalized are not effective against the omicron variant, doctors say. And the monoclonal antibody treatment that does seem to work, sotrovimab, is in very short supply in North Carolina.'

From XVs earlier post:

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext

'Interpretation
Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.'

I think you've nailed it manifesto.

Successful P3 means commercialisation and in pharma those numbers are in the billions.

'Experts in event based Investments'

Excellent find. Thanks for sharing.

This was the thread re the futility analysis. Reading it back some of this z score business is well over my head (tho it certainly didn't stop me getting excited about it), but it would seem that not being privvy to the thresholds chosen by SNG, we are unable to estimate the efficacy shown in the first 300 patients.

Please do correct me if I'm wrong on this one, but doesn't passing the futility assessment at 300 patients imply a certain level of efficacy? I recall the details being discussed on here a while back but can't find the thread.

Wow - in under 90 seconds...

10-Jan-22 13:24:18 202.40 70,000 Buy* 141.68k
10-Jan-22 13:23:58 201.60 1,250 Unknown* 2,520
10-Jan-22 13:23:53 202.40 100 Buy* 202.40 A
10-Jan-22 13:23:51 202.40 2,880 Buy* 5,829 A
10-Jan-22 13:23:51 202.40 19,757 Buy* 39.99k A
10-Jan-22 13:23:46 202.40 17,531 Buy* 35.48k A
10-Jan-22 13:23:46 202.40 68,023 Buy* 137.68k

Would think that if there were any US based partners involved (NIH or otherwise) any joint statement/release would need to be timed for both parties. From a purely marketing POV, from about 11AM GMT you're covering both Europe and Americas.

All that said, I think Matml's point is a good one as well.

Channeling the patience of Buddha today ;-)

Bumping in regards the 'good RNS' thread.

Every day is a school day.

This is the one https://youtu.be/dSTE_-UuZI4

Bit dry but some decent info, nothing we don't already know

Matterhorn shared a YouTube clip a couple weeks back of one of the lead chaps on A2 explaining the trials, if I recall correctly, he seemed to imply that P3 would go forward differently than how they first envisioned - perhaps it's because they didn't expect an inhaled treatment or that only 2 would graduate to P3. There's a lot of detailed info if anyone cares to dig the post up.

Strongly suggest any visitors to this board keep in mind the above accounts are all professional... ( And likely run out of the same office with a few different admins)

So much this. Excellent post Axe.

'Greg *****, Global President of Ashfield Engage, said: “It is a privilege to support Synairgen in bringing this innovative potential treatment to COVID-19 patients. Having initially collaborated with Synairgen regarding patient support, we have together developed a truly consultative approach – taking the time to fully understand patient needs and providing solutions in both hospital and home settings.'

Hospital AND home....

Will almost def be post close, like clockwork at this point.

https://www.washingtonpost.com/us-policy/2022/01/07/white-house-covid-aid/

'But officials in the White House Office of Management and Budget and Department of Health and Human Services have started putting together a longer-term funding request that is expected to ask Congress for tens of billions of dollars more, likely centered around covid therapeutics and ramping up vaccine distribution, the people said.'

H/t @downunderfutbol on twitter

I do really enjoy this one tbh.

Bit of Friday science for our newcomer...